1991
DOI: 10.1177/0192623391019004-116
|View full text |Cite
|
Sign up to set email alerts
|

Alveolar Proteinosis and Phospholipidoses of the Lungs

Abstract: Three pulmonary disease conditions result from the accumulation of phospholipids in the lung. These conditions are the human lung disease known as pulmonary alveolar proteinosis, the lipoproteinosis that arises in the lungs of rats during acute silicosis, and the phospholipidoses induced by numerous cationic amphiphilic therapeutic agents. In this paper, the status of phospholipid metabolism in the lungs during the process of each of these lung conditions has been reviewed and possible mechanisms for their est… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
42
0
5

Year Published

1996
1996
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 32 publications
(48 citation statements)
references
References 219 publications
1
42
0
5
Order By: Relevance
“…The improvement of symptoms with surfactant administration in this infant and in another child with TTF-1 deficiency (7) is clinical evidence supporting a surfactant abnormality component. In contrast to genetic disorders of surfactant function (i.e., SP-B and ABCA3 deficiencies), wherein lamellar bodies are reduced, absent, or abnormally formed (30)(31)(32)(33), or alveolar proteinosis, wherein there is accumulation of phospholipid membranes and abnormal tubular myelin (34), the ultrastructure of the lamellar bodies in this infant appeared normal and were abundant in alveolar lumens. Tubular myelin was not seen, but is generally not observed in lung specimens routinely examined by electron microscopy (Reference [35] and personal observations, A.R.P-A.).…”
Section: Discussionmentioning
confidence: 59%
“…The improvement of symptoms with surfactant administration in this infant and in another child with TTF-1 deficiency (7) is clinical evidence supporting a surfactant abnormality component. In contrast to genetic disorders of surfactant function (i.e., SP-B and ABCA3 deficiencies), wherein lamellar bodies are reduced, absent, or abnormally formed (30)(31)(32)(33), or alveolar proteinosis, wherein there is accumulation of phospholipid membranes and abnormal tubular myelin (34), the ultrastructure of the lamellar bodies in this infant appeared normal and were abundant in alveolar lumens. Tubular myelin was not seen, but is generally not observed in lung specimens routinely examined by electron microscopy (Reference [35] and personal observations, A.R.P-A.).…”
Section: Discussionmentioning
confidence: 59%
“…One problem with surfactant overproduction is that sustained and uncontrolled over a period of time, it can become a pathological feature of silica exposure. Proteinosis and phospholipidosis of the lungs, secondary to silicosis, is characterized by appearance of tubular myelin-like multilamellated structures in the alveoli and distal airways [34].…”
Section: Modification Of Silica Toxicity By Lung Surfactantmentioning
confidence: 99%
“…After secretion, alveolar forms of surfactant include these lamellar bodies, highly organised structures termed tubular myelin, and monolayered and multilayered, phospholipid-rich sheets and vesicles (Whitsett and Weaver, 2002). While the principal function of this pulmonary surfactant is the regulation of surface tension in the lungs (Nicholas, 1996), it is also postulated that increased production of this surfactant may play a role in defending the lungs against chemical and particulate damage (Hook, 1991(Hook, , 1993.…”
Section: Mtt Reduction (% Control)mentioning
confidence: 99%